AHOD1331-A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents

Grant

Date/time Interval

  • March 23, 2018 - March 22, 2025
  • Total Award Amount

  • 1162.00
  • Direct Costs

  • 924.00
  • Sponsor Award Id

  • Contributor

  • Ana Galtarossa Xavier   Investigator  
  • Julie Wolfson-Stockman M.D.   Investigator  
  • Matthew Kutny M.D.   Principal Investigator